IPX 233

Drug Profile

IPX 233

Alternative Names: IPX-233; IPX233 ER C0003; IPX233-C0001; IPX233-C0002; IPX233-T0001; IPX233-T0002

Latest Information Update: 15 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Impax Pharmaceuticals
  • Class
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
  • 01 Jan 2015 Impax Pharmaceuticals terminates phase I trial of an extended release capsule in Healthy volunteers in Australia (ACTRN12614000518662)
  • 01 Aug 2014 IPX 233 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top